A new Nexium lawsuit has been filed in Tennessee federal court on behalf of a woman who was diagnosed with severe, drug-induced chronic kidney disease following treatment with the popular heartburn drug. The June 26th filing claims that AstraZeneca failed to warn patients that Nexium could cause serious harm to the kidneys.
Nexium is AstraZeneca’s best-selling drug, with sales exceeding $5.2 billion in 2008. Like other proton pump inhibitors, it is indicated to treat GERD and other digestive disorders associated with the excess production of stomach acid.
According to a complaint now pending in the U.S. District Court, Eastern District of Tennessee, Andranette Tate began taking Nexium in November 2010 to treat GERD and a duodenal ulcer. She continued to take the drug until January 2014. Tate was diagnosed with severe, drug-induced chronic kidney disease, stage III, in September 2013. She alleges that her kidney injuries were caused by Nexium.
“Recent studies have shown the long-term use of PPIs was independently associated with a 20% to 50% higher risk of incident chronic kidney disease (“CKD”), after adjusting for several potential confounding variables, including demographics, socioeconomic status, clinical measurements, prevalent comorbidities, and concomitant use of medications,” the complaint states. “In one of those studies, the use of PPIs for any period of time was shown to increase the risk of CKD by 10%.”
Tate contends that AstraZeneca and other defendants “completely failed” to provide Nexium users with any warnings regarding chronic kidney disease.
“In omitting, concealing, and inadequately providing critical safety information regarding the use of Nexium in order to induce its purchase and use, Defendants engaged in and continue to engage in conduct likely to mislead consumers including Plaintiff. This conduct is fraudulent, unfair, and unlawful.”
Similar kidney damage lawsuits have been filed against other proton pump inhibitor manufacturers, including the makers of Prilosec, PrevAcid, Protonix and Dexilant. In June, plaintiffs petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) to centralize all federally-filed cases in a single U.S. District Court for the purpose of coordinated pretrial proceedings. The Panel will hear oral arguments on the matter during its July 27th Hearing Session in Los Angeles, California.
The JPML declined to grant a similar request in February. However, there were only about 15 proton pump inhibitor lawsuits pending in federal courts at that time. According to the plaintiffs’ latest motion, the litigation involving proton pump inhibitors and kidney injuries has grown to include at least 172 claims.
The Nexium lawyers at Bernstein Liebhard LLP are actively filing proton pump inhibitor lawsuits involving chronic kidney disease and other serious renal complications. To learn more, please contact our office at (888) 994-5118.